截至2026年2月25日 13:49，中证医药及医疗器械创新指数(931484)上涨0.71%，成分股三生国健上涨 8.16%，浙江医药上涨4.83%，南微医学上涨3.45%，新和成上涨2.80%，康龙化成上涨2.16%。医疗创新 ETF(516820)上涨0.55%，最新价报0.36元。 医药板块结构性机会持续深化，AI医疗与脑机接口成为短期主线。消息面上，常州市第一人民医院门 诊大厅内，两个人形机器人"智能导诊员"正式上岗。它们不仅具备预检分诊、信息查询等功能，还能与 患者握手互动，让就医更高效、更有温度。 中信建投证券认为，春节前后A股脑机接口板块部分个股大幅上涨，港股手术机器人公司亦因中标进展 获正面催化；叠加恒瑞医药IL-15疗法启动NMIBC三期、亚盛医药BTK PROTAC进入美国一期临床、和 铂医药新一代CTLA-4抗体通过NewCo出海等密集管线进展，创新药械"从0到1"逻辑正从前端研发向临 床验证与商业化环节传导，AI驱动的靶点发现、药物设计及智能诊疗设备有望成为中长期核心赛道。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取 ...

Group 1 - The year 2026 marks the beginning of the "15th Five-Year Plan," which is crucial for both current and future economic development in China [1] - The "14th Five-Year Plan" saw China maintain economic stability through consistent policy direction, achieving a GDP growth of over 140 trillion RMB by 2025 [2] - The external environment is becoming increasingly complex, with trade tensions and geopolitical conflicts posing challenges to global economic activities [2] Group 2 - Domestic demand is identified as a key focus for policy efforts, with an average contribution rate of 86.8% to economic growth from 2021 to 2024, and nearly 60% from final consumption expenditure [3] - The government is implementing various measures to stimulate consumption, including a new round of subsidies and initiatives to enhance service consumption and diversify consumption scenarios [3] - A strategic plan for expanding domestic demand from 2026 to 2030 is being developed to address structural imbalances in supply and demand [3] Group 3 - The Central Political Bureau's focus on future industries highlights the importance of strategic planning in the face of global technological and industrial changes [4] - The "15th Five-Year Plan" aims to promote emerging sectors such as quantum technology, biomanufacturing, hydrogen energy, and sixth-generation mobile communication as new economic growth points [4] - The role of private enterprises is emphasized, with increased policy support to stimulate innovation and development in future industries [4]

Group 1 - The A-share pharmaceutical sector rebounded, with medical device stocks and AI healthcare concepts leading the gains, including Meinian Health and Lepu Medical rising over 3% [1] - The largest medical ETF in the market (512170) saw a near 1% increase, with a net subscription of 77.77 million yuan on the previous day [1][5] - A new policy from the Beijing-Tianjin-Hebei region aims to enhance clinical trial efficiency and reduce compliance costs for CXO and medical device companies, set to take effect on March 1, 2026 [3] Group 2 - The pharmaceutical sector stabilized, with innovative drug concepts showing mixed results; Sanofi's stock rose over 3%, while Dizhe Pharmaceutical fell over 4% [3] - The only ETF tracking the pharmaceutical index (562050) turned positive during trading [3] - The FDA's recent announcement to establish a single pivotal clinical trial as the default standard for new drug approvals is expected to shorten development cycles and lower capital costs, benefiting innovative drug companies [4]

Group 1 - The A-share pharmaceutical sector has rebounded, with medical device stocks and AI healthcare concepts leading the gains, including significant increases in companies like Meinian Health and Lepu Medical [1][8] - The largest medical ETF in the market (512170) saw a nearly 1% increase, with a net subscription of 77.77 million yuan the previous day [1][8] - A new policy from the Beijing-Tianjin-Hebei region is expected to benefit CXO and medical device companies by improving clinical trial efficiency and reducing compliance costs [2][5][10] Group 2 - The FDA has announced a new default standard for drug approvals, allowing for a single key clinical trial plus confirmatory evidence, which is projected to shorten development cycles and reduce capital costs significantly [4][12] - The cost of a single key trial is estimated to range from 30 million to 150 million USD, which will enhance the research efficiency of innovative drug companies [4][12] - The medical ETF (512170) has over 50% weight in medical devices and more than 25% in CXO, covering 12 AI medical and brain-computer interface concept stocks [4][12] Group 3 - The pharmaceutical sector is stabilizing, with mixed performance among innovative drug concepts; companies like Sanofi and Dizhiyuan have shown notable fluctuations [2][10] - Traditional Chinese medicine stocks have generally risen, with companies like Darentang and Jilin Aodong seeing increases of over 2% [2][10] - The only ETF tracking the pharmaceutical index (562050) turned positive during trading, indicating a recovery in the sector [2][10]

Core Viewpoint - The medical device sector is experiencing a rebound, driven by policy support, technological advancements, and a shift towards domestic innovation and global competition [1][4]. Group 1: Medical Device Sector Performance - On February 25, the medical device sector saw a rebound with the medical device index ETF (159898) rising by 0.90%, following a net subscription of 1.67 million yuan the previous trading day [1]. - Key stocks such as Aidi Te, Zhend Medical, and Lepu Medical saw significant gains, with Aidi Te rising over 5% and others like Hualan Biological and Yuyue Medical also showing strong performance [1]. Group 2: Brain-Computer Interface Developments - The brain-computer interface (BCI) sector is accelerating, with significant policy backing and capital investment. A semi-invasive BCI company, Borui Kang, is preparing for a listing on the Sci-Tech Innovation Board [4]. - The global BCI market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - In China, the BCI market is expected to reach 3.2 billion yuan in 2024 and grow to 6.14 billion yuan by 2028 [4]. Group 3: Export Resilience and Growth - China's medical device exports demonstrated strong resilience, with a total export value of $45.542 billion in the first 11 months of 2025, marking a year-on-year increase of 3.82% [5]. - The export structure is evolving, with significant growth in high-end products such as hospital diagnostic and treatment equipment, which increased by 8.36% [5]. Group 4: Domestic Market and Innovation - The implementation of the fifth batch of national high-value medical consumables procurement has significantly reduced prices, such as the cost of cochlear implants dropping from over 200,000 yuan to around 50,000 yuan [7]. - The domestic medical device market is projected to reach 1,017.4 billion yuan by 2026, with a CAGR of approximately 5.9% to 6.6% from 2020 to 2035, driven by aging population, equipment upgrades, and technological innovation [7]. - In 2025, a total of 3,402 medical device products were approved, including 76 innovative devices, maintaining a high approval rate for three consecutive years [7]. Group 5: ETF Performance - The medical device index ETF (159898) tracks the CSI All Medical Device Index, focusing on the medical equipment, consumables, and in vitro diagnostics sectors, with a notable exposure to the BCI concept at 23.79% [9]. - Since its inception, the ETF has achieved a total return of 1,015.07%, with an annualized return of 12.52% and a one-year annualized return of 20.86% [9]. - The revenue and net profit of the ETF's constituent stocks have shown a year-on-year recovery, indicating a gradual improvement in the industry's fundamentals [9].

Economic Policies and Market Trends - The Chinese government emphasizes the development of the silver economy and elderly care services, aiming to enhance consumption capacity and create new consumption scenarios for the aging population [1] - The People's Bank of China plans to conduct a 600 billion yuan MLF operation to maintain liquidity in the banking system, marking a net injection of 300 billion yuan through MLF in February [1] - The domestic fuel prices have increased, with gasoline and diesel prices rising by 175 yuan/ton and 170 yuan/ton respectively, leading to retail prices of 6.7-6.9 yuan/liter for diesel and 7.0-7.1 yuan/liter for 92-octane gasoline [2] Capital Market Developments - Insurance institutions are optimistic about domestic investment assets, particularly stocks and securities investment funds, with a slight increase in A-share allocation expected by 2026 [4] - The Hong Kong stock market shows signs of recovery, with a notable performance in the semiconductor sector, driven by AI advancements and upcoming earnings disclosures [4] - Bitcoin and other cryptocurrencies have seen a decline, with Bitcoin dropping below $63,000 and the overall cryptocurrency market losing over $48 billion in value [6] Industry Highlights - The lithium carbonate market experienced a significant surge, with prices rising over 11%, attributed to bullish reports from top investment research firms [9] - The robotics sector is advancing with the launch of a new quadruped robot by Yushu Technology, showcasing enhanced performance and capabilities [9] - The storage chip market is expected to see price increases throughout the year, driven by AI and computing demands, with China's industry growth playing a crucial role [10] Company-Specific News - Dongyangguang is planning to acquire control of Yichang Dongshu No.1 Investment Co., with the transaction expected to constitute a major asset restructuring [11] - Tongwei Co. is set to purchase 100% of Qinghai Lihua Qing Energy Co. through a share issuance and cash payment, without changing its controlling shareholder [11] - AMD's stock surged over 7% following a significant chip agreement with Meta, involving the deployment of high-performance GPUs in AI data centers [6]

精锋医疗、北芯生命等医疗器械股接连上市，涨势颇佳；脑机接口引发一二级市场集体狂欢，博睿康、强脑科技冲刺IPO，上海另一家侵入式脑机创业公司 估值也超过45亿元。 如今，超百家医疗公司在港股排队，IPO政策即将收紧的风声广为流传，甚至有行业人士认为"新股破发30%会成为常态"。那么，2026年医疗公司上市的窗 口和机遇究竟如何？拟IPO公司正如何聪明地应对行情风险？ 去年创新药板块创造了许多财富神话：6000倍打新"认购王"、百余家公司年内股价翻倍等。2026年，更多基石和早期投资人会相继解禁，情绪与浮华褪去， 还得靠硬实力撑住长期市值。BD交易的规模和结构，仍是市场判断药企和新药分子质地的关键。 历经一年洗礼，资本市场对于创新药License-out（对外授权）的反应愈发理性，"BD拉不动股价"也时有发生。2026年MNC对中国新药资产的热情不减，除 了已然拥挤的肿瘤赛道，哪些新方向正成为大药企竞逐的热点？ 新药BD授权的玩家中，AI native的生物医药公司已然不容小觑。近一个多月，英矽智能、华深智药等频获BD交易，国内某AI制药明星创业公司估值拉至30 亿美金。新药老炮儿们如何看待"AI科学家"在药物开 ...

中央网信办主任、国家网信办主任庄荣文在学习时报头版撰文指出，坚持赋能增效，体系化深层次推进 信息化发展。 加强统筹、把握重点、主动作为，健全推进信息化发展的政策体系和制度机制，整体推进数字化、网络 化、智能化协同发展。 着力推动网络信息技术创新突破，全链条推动集成电路、基础软件等重点领域关键核心技术取得决定性 突破，加快人工智能、区块链等数智技术创新，积极实施"人工智能+"行动。 着力推动网信产业生态发展，推动量子科技、具身智能、脑机接口、6G等成为新的经济增长点，加快 发展人工智能、操作系统、数据库等生态，深入推进数字化绿色化协同转型发展，促进网信企业高质量 发展。 着力推动信息基础设施优化升级，推进区块链赋能航（货）运贸易数字化等应用场景，深化IPv6技术创 新和融合应用，深化数据资源开发利用，推进数据高效便利安全跨境流动。 着力推动网信为民，提升电子政务服务效能，规范政务移动互联网应用程序管理，运用数智技术赋能民 生服务，扎实推进数字乡村强农惠农富农，提升全民数智素养，提高人民群众数字化生活品质。 以下为原文： 锚定网络强国战略目标推进"十五五"网信事业实现良好开局 中央宣传部副部长，中央网信办主任、国 ...

中央宣传部副部长，中央网信办主任、国家网信办主任庄荣文在《学习时报》头版撰文指出，坚持赋能 增效，体系化深层次推进信息化发展。加强统筹、把握重点、主动作为，健全推进信息化发展的政策体 系和制度机制，整体推进数字化、网络化、智能化协同发展。着力推动网络信息技术创新突破，全链条 推动集成电路、基础软件等重点领域关键核心技术取得决定性突破，加快人工智能、区块链等数智技术 创新，积极实施"人工智能+"行动。着力推动网信产业生态发展，推动量子科技、具身智能、脑机接 口、6G等成为新的经济增长点，加快发展人工智能、操作系统、数据库等生态，深入推进数字化绿色 化协同转型发展，促进网信企业高质量发展。着力推动信息基础设施优化升级，推进区块链赋能航 （货）运贸易数字化等应用场景，深化IPv6技术创新和融合应用，深化数据资源开发利用，推进数据高 效便利安全跨境流动。着力推动网信为民，提升电子政务服务效能，规范政务移动互联网应用程序管 理，运用数智技术赋能民生服务，扎实推进数字乡村强农惠农富农，提升全民数智素养，提高人民群众 数字化生活品质。 （文章来源：第一财经） ...

格隆汇2月24日丨宜安科技(300328.SZ)在投资者互动平台表示，公司暂未涉及脑机接口相关产品。 ...